Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Profit After Tax (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Profit After Tax data on record, last reported at -$34.9 million in Q3 2025.

  • For Q3 2025, Profit After Tax fell 427.31% year-over-year to -$34.9 million; the TTM value through Sep 2025 reached -$108.9 million, up 19.23%, while the annual FY2024 figure was -$97.9 million, 62.01% up from the prior year.
  • Profit After Tax reached -$34.9 million in Q3 2025 per SGMO's latest filing, down from -$20.0 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $21.1 million in Q1 2023 and bottomed at -$114.5 million in Q2 2023.
  • Average Profit After Tax over 5 years is -$42.7 million, with a median of -$44.0 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: crashed 3062.33% in 2021, then soared 148.05% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$37.5 million in 2021, then crashed by 38.61% to -$52.0 million in 2022, then fell by 16.01% to -$60.3 million in 2023, then soared by 61.2% to -$23.4 million in 2024, then plummeted by 49.3% to -$34.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$34.9 million in Q3 2025, -$20.0 million in Q2 2025, and -$30.6 million in Q1 2025.